المؤلفون: Shortt J., Johnstone R.W., Waibel M., Gregory G.

مصطلحات الفهرس: B cell lymphoma/dt [Drug Therapy], b cell precursor acute lymphoblastic leukemia/dt [Drug Therapy], cancer combination chemotherapy, cancer survival, gene expression profiling, gene sequence, germinal center, Hodgkin disease, human, large cell lymphoma/dt [Drug Therapy], oncogene myc, phase 1 clinical trial (topic), phase 2 clinical trial (topic), phase 3 clinical trial (topic), priority journal, protein expression, randomized controlled trial (topic), review, signal transduction, treatment outcome, virus oncogene, 4 [4 (4' chloro 2 biphenylylmethyl) 1 piperazinyl] n [4 [3 dimethylamino 1 (phenylthiomethyl)propylamino] 3 nitrobenzenesulfonyl]benzamide/dt [Drug Therapy], antineoplastic agent/dt [Drug Therapy], bleomycin/cb [Drug Combination], bleomycin/dt [Drug Therapy], bortezomib/cb [Drug Combination], bortezomib/dt [Drug Therapy], carfilzomib/cb [Drug Combination], carfilzomib/dt [Drug Therapy], mammalian target of rapamycin/ec [Endogenous Compound], navitoclax/dt [Drug Therapy], nilotinib/dt [Drug Therapy], panobinostat/dt [Drug Therapy], phosphatidylinositol 3 kinase/ec [Endogenous Compound], pidilizumab/dt [Drug Therapy], prednisone/cb [Drug Combination], prednisone/dt [Drug Therapy], protein bcl 2/ec [Endogenous Compound], protein kinase B/ec [Endogenous Compound], rituximab/cb [Drug Combination], rituximab/dt [Drug Therapy], ruxolitinib/dt [Drug Therapy], STAT protein/ec [Endogenous Compound], unindexed drug, venetoclax/dt [Drug Therapy], vincristine/cb [Drug Combination], vincristine/dt [Drug Therapy], vindesine/cb [Drug Combination], vindesine/dt [Drug Therapy], germinal center B cell like diffuse large b cell lymphoma, activated B cell like diffuse large b cell lymphoma/dt [Drug Therapy], cyclophosphamide/cb [Drug Combination], cyclophosphamide/dt [Drug Therapy], dasatinib/dt [Drug Therapy], doxorubicin/cb [Drug Combination], doxorubicin/dt [Drug Therapy], etoposide/cb [Drug Combination], etoposide/dt [Drug Therapy], everolimus/dt [Drug Therapy], fedratinib/dt [Drug Therapy], ibrutinib/dt [Drug Therapy], idelalisib, imatinib/dt [Drug Therapy], Janus kinase/ec [Endogenous Compound], acute lymphoblastic leukemia/dt [Drug Therapy], B cell leukemia/dt [Drug Therapy], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/42028
Current Opinion in Hematology
Click here for full text options
LibKey Link

المؤلفون: Shortt J., Johnstone R.W., Waibel M., Gregory G.

مصطلحات الفهرس: B cell lymphoma/dt [Drug Therapy], b cell precursor acute lymphoblastic leukemia/dt [Drug Therapy], cancer combination chemotherapy, cancer survival, gene expression profiling, gene sequence, germinal center, Hodgkin disease, human, large cell lymphoma/dt [Drug Therapy], oncogene myc, phase 1 clinical trial (topic), phase 2 clinical trial (topic), phase 3 clinical trial (topic), priority journal, protein expression, randomized controlled trial (topic), review, signal transduction, treatment outcome, virus oncogene, 4 [4 (4' chloro 2 biphenylylmethyl) 1 piperazinyl] n [4 [3 dimethylamino 1 (phenylthiomethyl)propylamino] 3 nitrobenzenesulfonyl]benzamide/dt [Drug Therapy], antineoplastic agent/dt [Drug Therapy], bleomycin/cb [Drug Combination], bleomycin/dt [Drug Therapy], bortezomib/cb [Drug Combination], bortezomib/dt [Drug Therapy], carfilzomib/cb [Drug Combination], carfilzomib/dt [Drug Therapy], mammalian target of rapamycin/ec [Endogenous Compound], navitoclax/dt [Drug Therapy], nilotinib/dt [Drug Therapy], panobinostat/dt [Drug Therapy], phosphatidylinositol 3 kinase/ec [Endogenous Compound], pidilizumab/dt [Drug Therapy], prednisone/cb [Drug Combination], prednisone/dt [Drug Therapy], protein bcl 2/ec [Endogenous Compound], protein kinase B/ec [Endogenous Compound], rituximab/cb [Drug Combination], rituximab/dt [Drug Therapy], ruxolitinib/dt [Drug Therapy], STAT protein/ec [Endogenous Compound], unindexed drug, venetoclax/dt [Drug Therapy], vincristine/cb [Drug Combination], vincristine/dt [Drug Therapy], vindesine/cb [Drug Combination], vindesine/dt [Drug Therapy], germinal center B cell like diffuse large b cell lymphoma, activated B cell like diffuse large b cell lymphoma/dt [Drug Therapy], cyclophosphamide/cb [Drug Combination], cyclophosphamide/dt [Drug Therapy], dasatinib/dt [Drug Therapy], doxorubicin/cb [Drug Combination], doxorubicin/dt [Drug Therapy], etoposide/cb [Drug Combination], etoposide/dt [Drug Therapy], everolimus/dt [Drug Therapy], fedratinib/dt [Drug Therapy], ibrutinib/dt [Drug Therapy], idelalisib, imatinib/dt [Drug Therapy], Janus kinase/ec [Endogenous Compound], acute lymphoblastic leukemia/dt [Drug Therapy], B cell leukemia/dt [Drug Therapy], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/42028
Current Opinion in Hematology
Click here for full text options
LibKey Link